ZeSS: A Prospective Observational Safety Study of Patients With BRAF-V600 Mutation-positive Unresectable or Metastatic Melanoma Treated With Vemurafenib (ZelborafÂź)
ZeSS: A Prospective Observational Safety Study of Patients With BRAF-V600 Mutation-positive Unresectable or Metastatic Melanoma Treated With Vemurafenib (ZelborafÂź)
This multi-center, prospective, observational safety study will evaluate the safety and effectiveness of Zelboraf (vemurafenib) in a real world setting. Data from Zelboraf-treated patients with BRAF-V600 mutation-positive unresectable or metastatic melanoma will be collected for 2 years.
Inclusion Criteria:
Exclusion Criteria:
Berlin, 12200, Germany
Dresden, 01307, Germany
Greifswald, 17487, Germany
Jena, 07743, Germany
Leer, 26789, Germany
Ludwigshafen, 67063, Germany
LĂŒbeck, 23538, Germany
MĂŒnster, 48149, Germany
Quedlinburg, 06484, Germany
Recklinghausen, 45657, Germany
Rostock, 18057, Germany
WĂŒrzburg, 97080, Germany
Bologna, Emilia-Romagna 40138, Italy
Modena, Emilia-Romagna 41100, Italy
Rimini, Emilia-Romagna 47922, Italy
Milan, Lombardy 20162, Italy
Siena, Tuscany 53100, Italy
Maastricht, 6229 HX, Netherlands
Warsaw, 02-781, Poland
Dorchester, DT1 2JY, United Kingdom